Search Results

ZymoGenetics and Serono to continue testing of B-cell cancer treatment.

Subjects: ANTINEOPLASTIC agents; B cell lymphoma; CLINICAL trialsZYMOGENETICS Inc. ZYMOGENETICS Inc. ZYMOGENETICS Inc. 017854688 ; UNITED States. Food & Drug Administration ; SERONO Inc.

• Source: PharmaWatch: Cancer. November 2004, Vol. 3 Issue 11, p6-7. 2p.

Record details

Progen achieves efficacy endpoint in phase II multiple myeloma trial.

Subjects: *BIOTECHNOLOGY industries; MULTIPLE myeloma treatment; B cell lymphomaPROGEN Pharmaceuticals Ltd.

• Source: PharmaWatch: Cancer. August 2003, Vol. 2 Issue 8, p11-12. 2p.

Record details

Current Myeloma Treatment Paradigm: 10-15 Months of Treatment, Five Years of Survival.

Subjects: B cell lymphoma; MULTIPLE myeloma; MULTIPLE myeloma treatment

• Source: White Book - Multiple Myeloma: SCB Survey Highlights Growth Potential of New Agents. May2007, p7-8. 2p.

Record details

MedImmune and Micromet enter agreement to co-develop treatment for B cell tumors.

Subjects: *JOINT ventures; B cell lymphoma; DRUG developmentMEDIMMUNE Inc. 190639906 MEDIMMUNE Inc. MEDIMMUNE Inc. 190639906 190639906 MEDIMMUNE Inc. 190639906 MEDI; MICROMET Inc.

• Source: PharmaWatch: Cancer. July 2003, Vol. 2 Issue 7, p25-25. 1p.

Record details

Current Chemotherapy for MM: Thal, Then Vel, Then Rev.

Subjects: B cell lymphoma; MULTIPLE myeloma treatment; MULTIPLE myeloma

• Source: White Book - Multiple Myeloma: SCB Survey Highlights Growth Potential of New Agents. May2007, p15-20. 6p.

Record details

Overview.

• Authors : Porges, Geoffrey C. ; Guha, Amrita

Subjects: B cell lymphoma; MULTIPLE myeloma treatment; SURVEYS

• Source: White Book - Multiple Myeloma: SCB Survey Highlights Growth Potential of New Agents. May2007, p1-1. 1p.

Record details

Seattle Genetics discontinues Phase IIb lymphoma trial.

Subjects: DRUG efficacy; DRUG development; B cell lymphomaSEATTLE Genetics Inc. SEATTLE Genetics Inc. SEATTLE Genetics Inc. SGEN

• Source: PharmaWatch: Cancer. Nov2009, Vol. 8 Issue 11, p14-15. 2p.

Record details

Genzyme applies for expanded Campath label.

Subjects: DRUG labeling laws; B cell lymphoma; CHRONIC lymphocytic leukemia treatmentGENZYME Corp. 025322157 GENZYME Corp. GENZYME Corp. 025322157 025322157 GENZYME Corp. 025322157 GENZ

• Source: PharmaWatch: Cancer. May2007, Vol. 6 Issue 5, p5-6. 2p.

Record details

HODGKIN'S DISEASE.

Subjects: HODGKIN'S disease; LYMPHOMAS; B cell lymphoma

• Source: Hodgkin's Disease Annual Report; 1/17/2007, p1-14, 14p

Record details

Lilly lymphoma drug designated orphan status.

Subjects: CLINICAL trials; ORPHAN drugs; B cell lymphomaELI Lilly & Co.

• Source: PharmaWatch: Cancer; May2007, Vol. 6 Issue 5, p4-5, 2p

Record details